Limits...
Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine.

Wang XY, Lim-Jurado M, Prepageran N, Tantilipikorn P, Wang de Y - Ther Clin Risk Manag (2016)

Bottom Line: This agent does not interact with the cytochrome P450 system and does not undergo significant metabolism in humans, suggesting that it has very low potential for drug-drug interactions, and does not require dose adjustment in renal impairment.It has also shown significant efficacy (similar to that of cetirizine) and safety in the long-term treatment of perennial allergic rhinitis.Bilastine is generally well tolerated, both at standard and at supratherapeutic doses, appears to have less sedative potential than other second-generation antihistamines, and has no cardiotoxicity.

View Article: PubMed Central - PubMed

Affiliation: Department of Allergy, Beijing Shijitan Hospital, Capital Medical University, Beijing, People's Republic of China.

ABSTRACT
Allergic rhinitis and urticaria are common allergic diseases that may have a major negative impact on patients' quality of life. Bilastine, a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action. This agent does not interact with the cytochrome P450 system and does not undergo significant metabolism in humans, suggesting that it has very low potential for drug-drug interactions, and does not require dose adjustment in renal impairment. As bilastine is not metabolized and is excreted largely unchanged, hepatic impairment is not expected to increase systemic exposure above the drug's safety margin. Bilastine has demonstrated similar efficacy to cetirizine and desloratadine in patients with seasonal allergic rhinitis and, in a Vienna Chamber study, a potentially longer duration of action than fexofenadine in patients with asymptomatic seasonal allergic rhinitis. It has also shown significant efficacy (similar to that of cetirizine) and safety in the long-term treatment of perennial allergic rhinitis. Bilastine showed similar efficacy to levocetirizine in patients with chronic spontaneous urticaria and can be safely used at doses of up to fourfold higher than standard dosage (80 mg once daily). The fourfold higher than standard dose is specified as an acceptable second-line treatment option for urticaria in international guidelines. Bilastine is generally well tolerated, both at standard and at supratherapeutic doses, appears to have less sedative potential than other second-generation antihistamines, and has no cardiotoxicity. Based on its pharmacokinetic properties, efficacy, and tolerability profile, bilastine will be valuable in the management of allergic rhinitis and urticaria.

No MeSH data available.


Related in: MedlinePlus

Mean decreases in TSS during 4 weeks’ administration of bilastine or levocetirizine to patients with chronic spontaneous urticaria.Notes: *P<0.001 versus placebo. Reproduced from Zuberbier T, Oanta A, Bogacka E, et al; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy. 2010;65:516–528.61 With permission from John Wiley and Sons. Copyright ©2009.Abbreviation: TSS, total symptom score.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4835134&req=5

f8-tcrm-12-585: Mean decreases in TSS during 4 weeks’ administration of bilastine or levocetirizine to patients with chronic spontaneous urticaria.Notes: *P<0.001 versus placebo. Reproduced from Zuberbier T, Oanta A, Bogacka E, et al; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy. 2010;65:516–528.61 With permission from John Wiley and Sons. Copyright ©2009.Abbreviation: TSS, total symptom score.

Mentions: A 4-week, multicenter, randomized, double-blind, placebo-controlled study compared the efficacy of bilastine with that of levocetirizine in a total of 525 patients with chronic idiopathic urticaria.61 Bilastine and levocetirizine were similarly effective and both significantly more effective than placebo (P<0.001), in reducing mean TSS (for pruritus severity, number of wheals, and maximum size of wheals) over 2 weeks and 4 weeks (Figure 8).61 Significantly greater improvements than placebo were noted regarding reduction in Dermatology Life Quality Index score: bilastine −9.45 (P<0.001), levocetirizine −8.94 (P<0.001), and placebo −5.93.61


Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine.

Wang XY, Lim-Jurado M, Prepageran N, Tantilipikorn P, Wang de Y - Ther Clin Risk Manag (2016)

Mean decreases in TSS during 4 weeks’ administration of bilastine or levocetirizine to patients with chronic spontaneous urticaria.Notes: *P<0.001 versus placebo. Reproduced from Zuberbier T, Oanta A, Bogacka E, et al; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy. 2010;65:516–528.61 With permission from John Wiley and Sons. Copyright ©2009.Abbreviation: TSS, total symptom score.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4835134&req=5

f8-tcrm-12-585: Mean decreases in TSS during 4 weeks’ administration of bilastine or levocetirizine to patients with chronic spontaneous urticaria.Notes: *P<0.001 versus placebo. Reproduced from Zuberbier T, Oanta A, Bogacka E, et al; Bilastine International Working Group. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy. 2010;65:516–528.61 With permission from John Wiley and Sons. Copyright ©2009.Abbreviation: TSS, total symptom score.
Mentions: A 4-week, multicenter, randomized, double-blind, placebo-controlled study compared the efficacy of bilastine with that of levocetirizine in a total of 525 patients with chronic idiopathic urticaria.61 Bilastine and levocetirizine were similarly effective and both significantly more effective than placebo (P<0.001), in reducing mean TSS (for pruritus severity, number of wheals, and maximum size of wheals) over 2 weeks and 4 weeks (Figure 8).61 Significantly greater improvements than placebo were noted regarding reduction in Dermatology Life Quality Index score: bilastine −9.45 (P<0.001), levocetirizine −8.94 (P<0.001), and placebo −5.93.61

Bottom Line: This agent does not interact with the cytochrome P450 system and does not undergo significant metabolism in humans, suggesting that it has very low potential for drug-drug interactions, and does not require dose adjustment in renal impairment.It has also shown significant efficacy (similar to that of cetirizine) and safety in the long-term treatment of perennial allergic rhinitis.Bilastine is generally well tolerated, both at standard and at supratherapeutic doses, appears to have less sedative potential than other second-generation antihistamines, and has no cardiotoxicity.

View Article: PubMed Central - PubMed

Affiliation: Department of Allergy, Beijing Shijitan Hospital, Capital Medical University, Beijing, People's Republic of China.

ABSTRACT
Allergic rhinitis and urticaria are common allergic diseases that may have a major negative impact on patients' quality of life. Bilastine, a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action. This agent does not interact with the cytochrome P450 system and does not undergo significant metabolism in humans, suggesting that it has very low potential for drug-drug interactions, and does not require dose adjustment in renal impairment. As bilastine is not metabolized and is excreted largely unchanged, hepatic impairment is not expected to increase systemic exposure above the drug's safety margin. Bilastine has demonstrated similar efficacy to cetirizine and desloratadine in patients with seasonal allergic rhinitis and, in a Vienna Chamber study, a potentially longer duration of action than fexofenadine in patients with asymptomatic seasonal allergic rhinitis. It has also shown significant efficacy (similar to that of cetirizine) and safety in the long-term treatment of perennial allergic rhinitis. Bilastine showed similar efficacy to levocetirizine in patients with chronic spontaneous urticaria and can be safely used at doses of up to fourfold higher than standard dosage (80 mg once daily). The fourfold higher than standard dose is specified as an acceptable second-line treatment option for urticaria in international guidelines. Bilastine is generally well tolerated, both at standard and at supratherapeutic doses, appears to have less sedative potential than other second-generation antihistamines, and has no cardiotoxicity. Based on its pharmacokinetic properties, efficacy, and tolerability profile, bilastine will be valuable in the management of allergic rhinitis and urticaria.

No MeSH data available.


Related in: MedlinePlus